BTK T474I
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene BTK
Variant T474I
Impact List missense
Protein Effect no effect
Gene Variant Descriptions BTK T474I lies within the protein kinase domain of the Btk protein (UniProt.org). T474I demonstrates kinase activity similar to wild-type Btk in cultured cells (PMID: 27571029, PMID: 28573668, PMID: 33526860).
Associated Drug Resistance
Category Variants Paths

BTK mutant BTK T474I

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000061.3
gDNA chrX:g.101356197G>A
cDNA c.1421C>T
Protein p.T474I
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_000061 chrX:g.101356197G>A c.1421C>T p.T474I RefSeq GRCh38/hg38
NM_000061.2 chrX:g.101356197G>A c.1421C>T p.T474I RefSeq GRCh38/hg38
NM_000061.3 chrX:g.101356197G>A c.1421C>T p.T474I RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BTK T474I Advanced Solid Tumor predicted - sensitive Ibrutinib Preclinical - Biochemical Actionable In a preclinical study, treatment with Imbruvica (ibrutinib) resulted in reduced Btk activity in cell lines expressing BTK T474I in culture (PMID: 33526860). 33526860
BTK T474I chronic lymphocytic leukemia predicted - resistant Pirtobrutinib Case Reports/Case Series Actionable In a clinical case study, a patient with chronic lymphocytic leukemia harboring BTK C481S experienced progressive disease after an initial response on treatment with Jaypirca (pirtobrutinib) and was found to have acquired BTK T474I and lost BTK C481S (PMID: 39048721). 39048721
BTK T474I chronic lymphocytic leukemia predicted - resistant Pirtobrutinib Case Reports/Case Series Actionable In a clinical case study, two patients with chronic lymphocytic leukemia who previously responded to Jaypirca (pirtobrutinib) treatment were found to have acquired BTK T474I upon disease progression (PMID: 35196427). 35196427
BTK T474I diffuse large B-cell lymphoma sensitive Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, Imbruvica (ibrutinib) treatment inhibited phosphorylation of Btk and decreased viability of a diffuse large B-cell lymphoma cell line expressing BTK T474I in culture (PMID: 35196427). 35196427
BTK T474I diffuse large B-cell lymphoma resistant Pirtobrutinib Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK T474I demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 35196427). 35196427
BTK T474I diffuse large B-cell lymphoma resistant Pirtobrutinib Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK T474I demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 38301010). 38301010
BTK T474I diffuse large B-cell lymphoma resistant Fenebrutinib Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK T474I demonstrated resistance to Fenebrutinib (GDC-0853) in culture (PMID: 35196427). 35196427
BTK T474I diffuse large B-cell lymphoma resistant Vecabrutinib Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK T474I demonstrated resistance to Vecabrutinib (SNS-062) in culture (PMID: 35196427). 35196427
BTK T474I diffuse large B-cell lymphoma predicted - sensitive NX-5948 Preclinical - Cell culture Actionable In a preclinical study, NX-5948 inhibited Btk signaling and proliferation of a diffuse large B-cell lymphoma cell line expressing BTK T474I in culture (Cancer Res (2023) 83 (7_Supplement): 2850). detail...
BTK T474I diffuse large B-cell lymphoma sensitive NX-2127 Preclinical - Cell culture Actionable In a preclinical study, NX-2127 inhibited viability of a diffuse large B-cell lymphoma cell line expressing BTK T474I in culture (PMID: 38301010). 38301010
BTK T474I diffuse large B-cell lymphoma resistant Acalabrutinib Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK T474I demonstrated resistance to Calquence (acalabrutinib) in culture (PMID: 38301010). 38301010
BTK T474I chronic lymphocytic leukemia predicted - sensitive BGB-16673 Case Reports/Case Series Actionable In a clinical case study, BGB-16673 treatment resulted in reduction in bulky lymphadenopathy in a patient with chronic lymphocytic leukemia harboring BTK T474I (PMID: 39048721). 39048721
BTK T474I diffuse large B-cell lymphoma predicted - sensitive ONO-7018 Preclinical - Cell culture Actionable In a preclinical study, ONO-7018 inhibited proliferation of a diffuse large B-cell lymphoma cell line expressing BTK T474I in culture (Blood (2023) 142 (Supplement 1): 5779). detail...